US Patent Issued to CELLECTAR BIOSCIENCES on Dec. 23 for "Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy" (Connecticut Inventor)

ALEXANDRIA, Va., Dec. 23 -- United States Patent no. 12,503,479, issued on Dec. 23, was assigned to CELLECTAR BIOSCIENCES INC. (Madison, Wis.).

"Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy" was invented by Jarrod Longcor (East Haven, Conn.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are phospholipid ether (PLE) molecules. Further provided are phospholipid-flavagline conjugates. The phospholipid-flavagline conjugate may include a PLE conjugated to a flavagline via a linker. Further provided herein are methods of treating cancer in a subject and methods of targeting a drug to a tumor or cancer cell in a subject."

The patent was filed on Apri...